Onecrea Medical

News and Events

Upcoming Events

Onecrea Medical PCR London Valves 2025

PCR London Valves 2025 London

Onecrea Medical will be at PCR London Valves 2025. The conference will take place from November 16th to 18th at ExCeL London in London, UK. 

Learn More
Onecrea Medical TCT 2025

TCT 2025 San Francisco

Come connect with us at TCT 2025! TCT 2025 is from October 25th to 28th at the Moscone Center in San Francisco, California, USA. 

Learn More

News

Asia Intervention

Initial experience with the Crea Aortic Valve System – a first-in-human study

 March 2025

Transcatheter aortic valve implantation (TAVI) is a minimally invasive option for severe aortic…

Learn More
Screenshot 2023-07-28 084807 (2)

Onecrea Medical completes first-in-human implants of TAVR system

July 21, 2023
The company designed next-generation TAVR system to treat aortic stenosis…
Learn More
Screenshot 2023-07-28 084807 (3) (1)

Onecrea Medical announces successful first-in-human implants

July 20, 2023
First-in-human implants of its transcatheter aortic valve implantation…
Learn More
Screenshot 2023-07-28 084807 (3) (2)

Successful Completion of the First-in-human Implants of the Crea

July 21, 2023
While TAVR technology has been around since 2007, Onecrea Medical’s team …
Learn More
Screenshot 2023-07-28 084807 (1)

Onecrea Medical completes first-in-human implants of TAVR system

July 21, 2023
Onecrea Medical recently announced that it successfully completed first-in-human…
Learn More

Previous Events

rio valve 1 logo

PCR Rio Valves 2025 Rio De Janeiro

Come see the summary of Dr. Carlos Calderas’ presentations of the Crea Aortic Valve System at PCR Rio Valves 2025 in Rio de Janeiro.

Learn More
SOLACI-SOCIME-25-AGAVE-AZUL-2 2

SOLACI 2025 Mexico City

Dr. Flavio Ribichini presented the clinical studies for the Crea Aortic Valve System at SOLACI, the largest interventional cardiologist meeting in Latin America. 

Learn More
EuroPCR_image_responsive_4 2

EuroPCR 2025 Paris

Dr. Flavio Ribichini presented the clinical studies for the Crea Aortic Valve System at EuroPCR, the largest congress for interventional cardiovascular medicine in Europe.

Learn More
Screenshot 2024-02-21 144457

EuroPCR 2024 Paris

Dr. Flavio Ribichini presented the first-in-man study for the Crea Aortic Valve at EuroPCR, the largest congress for interventional cardiovascular medicine in Europe.

Learn More
Screenshot 2023-07-28 084807 (4)

CITIC 2023 Mexico City

Dr. Carlos Calderas presenting Crea Aortic Valve under Innovative and Next Generation TAVI …

Learn More
Scroll to Top

Dr. Carlos Calderas presenting the composite patient data for the ongoing Crea Aortic Valve System clinical trials.

Data from the ongoing clinical trials for the Crea Aortic Valve System (CAVS) were presented at PCR Rio Valves 2025 in Rio de Janeiro, Brazil. Dr. Carlos Calderas presented data from 6 cases in Venezuela and 15 cases in India. The patients were 16 elderly women and 5 elderly men (total average age of 71.1) with severe symptomatic aortic stenosis. All 21 patients had excellent hemodynamic data after implantation, including on average single-digit aortic mean gradients and statistically significant increases in aortic valvular area. Additionally, the NYHA classifications of all 21 patients improved post-procedure. The data shows much of the hemodynamic data improved as time went on, demonstrating the continued success of the self-anchoring and self-centering technology.

Dr. Carlos Calderas presenting in two sessions at PCR Rio Valves.

IMG_4070
IMG_4052

Click Below to Watch the Presentation Now

PCR Rio Valve Online 2025 (Timestamp 38:10)

Dr. Flavio Ribichini presenting the composite patient data for the ongoing Crea Aortic Valve System clinical trials.

SOLACI was created to advance and promote cardiovascular interventions in Latin America and the Caribbean. Here, Dr. Flavio Ribichini presented data from 6 cases in Venezuela and 14 cases in India of the Crea Aortic Valve System (CAVS). The patients were 16 elderly women and 4 elderly men with severe symptomatic aortic stenosis. All 20 patients had excellent hemodynamic data after implantation, including on average single-digit aortic mean gradients and improved NYHA classifications. Clinical trials still show that much of the hemodynamic data improved as time went on, indicating the success of the self-anchoring and self-centering technology.

The innovations of the Crea Aortic Valve System

The Crea Aortic Valve System is comprised of two valve implants: Altimus, a Wet TAVI valve in sizes 23mm, 26mm, 29mm, and Triumvir, a Dry TAVI valve in sizes 23mm, 26mm, 29mm. At SOLACI SOCIME’25 the advantages of the Onecrea Dry valve were demonstrated, including longterm durability and no anti-coagulation treatment required compared to mechanical valves, further reduced calcification than wet tissue, and ease of handling.

Dr. Flavio Ribichini presenting the composite patient data for the ongoing Crea Aortic Valve System clinical trials.

EuroPCR is one of the largest international congresses for interventional cardiologists. Here, Dr. Flavio Ribichini presented data from 6 cases in Venezuela and 10 cases in India of the Crea Aortic Valve System (CAVS). The patients were 14 elderly women and 2 elderly men with severe symptomatic aortic stenosis. All 16 patients had excellent hemodynamic data after implantation, including on average single-digit aortic mean gradients and trivial or no paravalvular leak. Additionally, the Vmax of all 16 patients was less than 2 m/s post-procedure. The data shows much of the hemodynamic data improved as time went on indicating the success of the self-anchoring and self-centering technology.

Click Below to Watch the Presentation Now

EuroPCR Online 2025

Dr. Flavio Ribichini presenting the 1-year data for the first Crea Aortic Valve patients.

EuroPCR is one of the largest international congresses for interventional cardiologists. Here, Dr. Flavio Ribichini presented the 1-year data for the first 3 patients of the Crea Aortic Valve (CAV). These cases were performed by Dr. Carlos Calderas in Venezuela. The patients were 3 elderly women with small aortic annuli and severe symptomatic aortic stenosis. All 3 patients had excellent hemodynamic data 1-year after implantation, including single-digit aortic mean gradients and trivial or no paravalvular leak. Additionally, the Vmax of all 3 patients was less than 2 m/s at 1 year. Interestingly, much of the hemodynamic data improved as time went on indicating the success of the self-anchoring and self-centering technology.

Onecrea Medical's Scientific Advisory Board Members and CEO

From Left to Right: Dr. Flavio Ribichini, Dr. Carlos Calderas, Dr. Maurizio Taramasso, Onecrea Medical CEO Kris Kupumbati

Crea Aortic Valve E-Poster on display in the Innovators Session

Dr. Carlos Calderas presenting Crea Aortic Valve under Innovative and Next Generation TAVI in CITIC 2023, Mexico City, Mexico.

CITIC is a training center for scientific, academic, research and communication resources where specialists in the cardiovascular area and doctors in training can find a platform for updating and communication with national and international experts in the area of ​​imaging and technology in cardiovascular intervention.